Tender Details
Ref No 23253592
Document

Tender Notice

Bidding

Not specified

Short Description

Ss-Contrast Medium Low Renal Toxicity 300/50Ml Vial-Pr 160177
Deadline *
Date 22 Dec 2025
* The estimated cost, values & dates are indicative only. Please read tender document for accurate information.
Client Address
Location Saudi Arabia
More Information
Know More

FREE Trial Plan For All New Users!

Start your Business.

Similar Tenders

  • Ref No: 8259327
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements According To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Hydrocortisone Cre 2 5 Mg N1

  • Deadline: 10 May 2026
  • Ref No: 8260726
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Hydrocortisone Tab 10 Mg

  • Deadline: 10 May 2026
  • Ref No: 5310892
  • Location: Germany

Drug Contracts With An Option To Join

  • Deadline: 01 May 2026
  • Ref No: 5306291
  • Location: Germany

Open House Drug Discount Agreements Rivaroxaban Film Coated Tablets Except With A Strength Of 2 5 Mg Atc B01Af01

  • Deadline: 05 Apr 2026
  • Ref No: 5304038
  • Location: Germany

Open House Drug Discount Contracts In Accordance With Section 130A Paragraph 8C Sgb V Pemetrexed Atc L01Ba04

  • Deadline: 16 Apr 2026
  • Ref No: 5301821
  • Location: Bulgaria

Delivery Of Medicinal Products Which Are Included In Appendix 2 Of The Pds For The Needs Of Umbal Kanev Ad

  • Deadline: 27 May 2027
  • Ref No: 5310172
  • Location: Germany

Open House Drug Discount Contracts In Accordance With Section 130A Paragraph 8C Sgb V Bortezomib Atc L01Xg01

  • Deadline: 16 Apr 2026
  • Ref No: 5396790
  • Location: Germany

Conclusion Of A Non Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For Medicinal Products Containing The Active Ingredient L

  • Deadline: 27 Apr 2026
  • Ref No: 5975224
  • Location: Germany

Conclusion Of A Non Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V By Means Of An Open House Model For The Active Ingred

  • Deadline: 30 Apr 2026
  • Ref No: 5226107
  • Location: Germany

Medicines With The Active Ingredient Combination Vilanterol Umeclidinium Bromide And Fluticasone Furoate Atc R03Al08

  • Deadline: 31 Mar 2026
  • Ref No: 5227518
  • Location: Germany

Medicines With The Active Ingredient Tiotropium Bromide Atc R03Bb04 Except In The Dosage Form Hard Capsules With Powder For Inhalation

  • Deadline: 31 Mar 2026
  • Ref No: 5976401
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Baclofen In The Dosage Form Inf

  • Deadline: 10 May 2026
  • Ref No: 5965319
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Acetylcysteine As An Otc Medi

  • Deadline: 10 May 2026
  • Ref No: 5968352
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Acetylcysteine In The Dosage

  • Deadline: 10 May 2026
WhatsApp Chat